An EORTC phase I study of capecitabine (Xeloda®) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer

European Journal of Cancer

Volumn 39, Issue 9, 2003, Pages 1277-1283

  Bonnefoi, H ^a   Biganzoli, L ^b   Mauriac, L ^c   Cufer, T ^d   Schaefer, P ^a   Atalay, G ^b   Piccart, M ^e  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b EORTC DATA CENTER   (Belgium)

^c INSTITUT BERGONIÉ   (France)

^d INSTITUTE OF ONCOLOGY   (Slovenia)

^e JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Capecitabine; Neoadjuvant chemotherapy; Phase I

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BACKACHE; BLOOD TOXICITY; BREAST CARCINOMA; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG INFUSION; ENZYME DEFICIENCY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEMORRHOID; HUMAN; HYPOKALEMIA; INFECTION; INSOMNIA; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; MYCOSIS; NAUSEA; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0038579645     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00266-1     Document Type: Article

References (19)

1. Jones A.L., Smith I.E., O'Brien M.E.R.et al. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer. an active new regimen J. Clin. Oncol. 12:1994;1259-1265.
2. Bonnefoi H., Smith I.E., O'Brien M.E.et al. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF). a very active and well-tolerated outpatient regimen Br. J. Cancer. 73:1996;391-396.
3. Hugli A., Sappino A.P., Anchisi S.et al. Infusional ECarboF in patients with advanced breast cancer. a very active and well-tolerated out-patient regimen Ann. Oncol. 11:2000;1557-1561.
4. Smith I.E., Walsh G., Jones A.et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J. Clin. Oncol. 13:1995;424-429.
5. Eisen T., Smith I.E., Johnston S.et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J. Clin. Oncol. 16:1998;1350-1357.
6. Wood W.C., Budman D.R., Korzun A.H.et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N. Engl. J. Med. 330:1994;1253-1259.
7. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors. 5-year follow-up results of French Adjuvant Study Group 05 randomized trial J. Clin. Oncol. 19:2001;602-611.
8. Bonnefoi H., Biganzoli L., Cufer T.et al. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer. Breast Cancer Res. Treat. 70:2001;55-63.
9. Miwa M., Ura M., Nishida M.et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer. 34:1998;1274-1281.
10. Ishikawa T., Utoh M., Sawada N.et al. Tumour selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol. 55:1998;1091-1097.
11. Cao S., Lu K., Ishitsuka H., Rustum Y.M. Antitumour efficacy of capecitabine against fluorouracil-sensitive and resistant tumours. Proc. Am. Soc. Clin. Oncol. 16:1997;795a.
12. Blum J.L., Jones S.E., Buzdar A.U.et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 17:1999;485-493.
13. Blum J.L., Dieras V., Lo Russo P.M.et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 92:2001;1759-1768.
14. Thuss-Patience P.C., von Minckwitz G., Luck H.et al. Capecitabine. a new standard in metastatic breast cancer recurring after anthracycline and taxane-containing chemotherapy? Results of a multicenter phase II trial Proc. Am. Soc. Clin. Oncol. 20:2001;2012a.
15. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS, March 1998.
16. WHO Handbook for Reporting Results of Cancer Treatment. 1979;WHO, Geneva, Switzerland.
17. Smith I.E., A'Hern R.P., Howell A.et al. Preoperative continuous infusional ECisF (epirubicin, cisplatin and infusional 5-FU) v. conventional AC chemotherapy for early breast cancer. a phase III multicentre randomised trial by the topic trial group Proc. Am. Soc. Clin. Oncol. 320:2000;320a.
18. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumours in human cancer xenografts. Cancer Res. 58:1998;685-690.
19. Beck A., Etienne M.C., Cheradame S.et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur. J. Cancer. 30A:1994;1517-1522.